Teva and Heptares enter agreement to develop small-molecule CGRP antagonists for migraines
Teva and Heptares Therapeutics announced a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide antagonists discovered by Heptares for the treatment of migraine. November 25, 2015